These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 25385703)

  • 1. Exploring the potential of monoclonal antibody therapeutics for HIV-1 eradication.
    Euler Z; Alter G
    AIDS Res Hum Retroviruses; 2015 Jan; 31(1):13-24. PubMed ID: 25385703
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells.
    Sung JA; Pickeral J; Liu L; Stanfield-Oakley SA; Lam CY; Garrido C; Pollara J; LaBranche C; Bonsignori M; Moody MA; Yang Y; Parks R; Archin N; Allard B; Kirchherr J; Kuruc JD; Gay CL; Cohen MS; Ochsenbauer C; Soderberg K; Liao HX; Montefiori D; Moore P; Johnson S; Koenig S; Haynes BF; Nordstrom JL; Margolis DM; Ferrari G
    J Clin Invest; 2015 Nov; 125(11):4077-90. PubMed ID: 26413868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal
    Garrido C; Abad-Fernandez M; Tuyishime M; Pollara JJ; Ferrari G; Soriano-Sarabia N; Margolis DM
    J Virol; 2018 Jun; 92(12):. PubMed ID: 29593039
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which therapeutic strategy will achieve a cure for HIV-1?
    Cillo AR; Mellors JW
    Curr Opin Virol; 2016 Jun; 18():14-9. PubMed ID: 26985878
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-HIV-1 ADCC and HIV-1 Env Can Be Partners in Reducing Latent HIV Reservoir.
    Suryawanshi P; Bagul R; Shete A; Thakar M
    Front Immunol; 2021; 12():663919. PubMed ID: 33995393
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The development of immune-modulating compounds to disrupt HIV latency.
    Remoli AL; Marsili G; Battistini A; Sgarbanti M
    Cytokine Growth Factor Rev; 2012; 23(4-5):159-72. PubMed ID: 22766356
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Autologous IgG antibodies block outgrowth of a substantial but variable fraction of viruses in the latent reservoir for HIV-1.
    Bertagnolli LN; Varriale J; Sweet S; Brockhurst J; Simonetti FR; White J; Beg S; Lynn K; Mounzer K; Frank I; Tebas P; Bar KJ; Montaner LJ; Siliciano RF; Siliciano JD
    Proc Natl Acad Sci U S A; 2020 Dec; 117(50):32066-32077. PubMed ID: 33239444
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Therapeutic approaches targeting HIV reservoirs].
    Cheret A
    Virologie (Montrouge); 2019 Aug; 23(4):250-259. PubMed ID: 31414662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Binding of antibodies to virion-associated gp120 molecules of primary-like human immunodeficiency virus type 1 (HIV-1) isolates: effect on HIV-1 infection of macrophages and peripheral blood mononuclear cells.
    Stamatatos L; Zolla-Pazner S; Gorny MK; Cheng-Mayer C
    Virology; 1997 Mar; 229(2):360-9. PubMed ID: 9126249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DC-based immunotherapy as strategy to purge the HIV reservoir?
    Søgaard OS
    EBioMedicine; 2019 May; 43():16-17. PubMed ID: 30981650
    [No Abstract]   [Full Text] [Related]  

  • 11. The role of latency reversal agents in the cure of HIV: A review of current data.
    Bashiri K; Rezaei N; Nasi M; Cossarizza A
    Immunol Lett; 2018 Apr; 196():135-139. PubMed ID: 29427743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic Targeting of HIV Reservoirs: How to Give T Cells a New Direction.
    Yang H; Wallace Z; Dorrell L
    Front Immunol; 2018; 9():2861. PubMed ID: 30564246
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HIV/AIDS. Report of novel treatment aimed at latent HIV raises the 'c word'.
    Cohen J
    Science; 2005 Aug; 309(5737):999-1000. PubMed ID: 16099956
    [No Abstract]   [Full Text] [Related]  

  • 14. Antibody-based candidate therapeutics against HIV-1: implications for virus eradication and vaccine design.
    Chen W; Ying T; Dimitrov DS
    Expert Opin Biol Ther; 2013 May; 13(5):657-71. PubMed ID: 23293858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. AIDS/HIV. Developing an AIDS vaccine: need, uncertainty, hope.
    Emini EA; Koff WC
    Science; 2004 Jun; 304(5679):1913-4. PubMed ID: 15218131
    [No Abstract]   [Full Text] [Related]  

  • 16. Reservoirs for HIV-1: mechanisms for viral persistence in the presence of antiviral immune responses and antiretroviral therapy.
    Pierson T; McArthur J; Siliciano RF
    Annu Rev Immunol; 2000; 18():665-708. PubMed ID: 10837072
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunologic control of HIV-1.
    Gandhi RT; Walker BD
    Annu Rev Med; 2002; 53():149-72. PubMed ID: 11818468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advancements in Developing Strategies for Sterilizing and Functional HIV Cures.
    Xu W; Li H; Wang Q; Hua C; Zhang H; Li W; Jiang S; Lu L
    Biomed Res Int; 2017; 2017():6096134. PubMed ID: 28529952
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An immune-selected point mutation in the transmembrane protein of human immunodeficiency virus type 1 (HXB2-Env:Ala 582(-->Thr)) decreases viral neutralization by monoclonal antibodies to the CD4-binding site.
    Klasse PJ; McKeating JA; Schutten M; Reitz MS; Robert-Guroff M
    Virology; 1993 Sep; 196(1):332-7. PubMed ID: 8356803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antibodies for Human Immunodeficiency Virus-1 Cure Strategies.
    Rossignol E; Alter G; Julg B
    J Infect Dis; 2021 Feb; 223(12 Suppl 2):22-31. PubMed ID: 33586772
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.